Andrew Hykes Sells 3,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock

Inari Medical, Inc. (NASDAQ:NARI) CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total transaction of $150,000.00. Following the transaction, the chief executive officer now directly owns 445,310 shares of the company’s stock, valued at approximately $22,265,500. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Inari Medical Stock Up 0.7 %

Shares of NARI opened at $48.74 on Friday. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $67.13. The firm’s fifty day moving average is $43.56 and its two-hundred day moving average is $45.99. The stock has a market cap of $2.85 billion, a PE ratio of -35.90 and a beta of 1.00.

Inari Medical (NASDAQ:NARI) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.25). The firm had revenue of $145.82 million for the quarter, compared to analyst estimates of $143.96 million. Inari Medical had a negative net margin of 13.68% and a negative return on equity of 10.09%. As a group, research analysts anticipate that Inari Medical, Inc. will post -0.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

NARI has been the subject of several recent analyst reports. Wells Fargo & Company cut their price target on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Inari Medical in a report on Friday, August 9th. They issued a “buy” rating and a $68.00 price target for the company. Robert W. Baird boosted their price target on shares of Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a report on Tuesday. Piper Sandler boosted their price target on shares of Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, Leerink Partnrs raised shares of Inari Medical to a “hold” rating in a report on Tuesday, September 3rd. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $58.89.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Inari Medical during the 1st quarter valued at about $30,000. GAMMA Investing LLC boosted its position in shares of Inari Medical by 164.7% during the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after acquiring an additional 438 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Inari Medical by 83.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock valued at $46,000 after acquiring an additional 435 shares during the last quarter. Covestor Ltd boosted its position in shares of Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock valued at $78,000 after acquiring an additional 376 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its position in shares of Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after acquiring an additional 522 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.